Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults
(QLAIV Trial)
Recruiting in Palo Alto (17 mi)
Overseen byAdriana Weinberg, MD
Age: < 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: University of Colorado, Denver
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The goal of this study is to determine if there is a difference in shedding (primary objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and HIV-negative children and young adults who are receiving the quadrivalent live-attenuated influenza vaccine (QLAIV).
Eligibility Criteria
Inclusion Criteria
Age 2-25
Only supposed to get one dose of vaccine for upcoming influenza season
No viral respiratory symptoms at time of immunization
See 5 more
Treatment Details
Interventions
- Quadrivalent Live Attenuated Influenza Vaccine (Virus Therapy)
Participant Groups
2Treatment groups
Active Control
Group I: QLAIV, HIV-infectedActive Control1 Intervention
QLAIV administered to HIV-infected individuals 2 to 25 yoa
Group II: QLAIV, HIV-uninfectedActive Control1 Intervention
QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Colorado DenverDenver, CO
Loading ...
Who Is Running the Clinical Trial?
University of Colorado, DenverLead Sponsor
MedImmune LLCIndustry Sponsor